Breast Cancer

Antibody-based therapy may be a novel addition to immunotherapies for breast cancer, lung cancer, and colon cancer.

A $450,000 research grant is targeting triple negative breast cancer and HER2-positive breast cancer.

Study provides better understanding of why some cancers are resistant to therapy.

High consumption of grilled, barbequed, or smoked meats may increase morality risk in breast cancer survivors.

A drug developed to treat cardiogenic shock may treat patients with triple negative breast cancer.

A personalized vaccine may effectively treat HER2-postive breast cancer.

Capsaicin derived from chili peppers shows promise on cultured triple-negative breast cancer cells.

Capsaicin could activate a receptor that prevents metastasis.

Identified cancer driver may be key to increasing survival in metaplastic breast cancer patients.

LJ is a 75-year-old patient with advanced breast cancer. She also has a medical history of hypertension and dementia. LJ decided to stop chemotherapy 2 months ago due to severe nausea, vomiting, and diarrhea.

The novel tool will be integrated into the National Cancer Institute’s current risk assessment tool.

Higher intake of grilled, barbecued, and smoked meats increases mortality risk among cancer survivors.

MYL-14010 is designed to treat certain types of human epidermal growth factor receptor 2 (HER2) positive breast cancers.

Top news of the day from across the healthcare landscape.

Combination approach better targets breast cancer tumors with PIK3CA gene mutations.

Combination therapy may help combat treatment resistance in cancer patients.

ASN003 is a drug that targets cancers driven by BRAF and PI3K.

Certain hypertension drugs block breast and pancreatic cancer invasion.

Top oncology articles of 2016 on Specialty Pharmacy Times.

New cancer-spreading protein discovered in groundbreaking study.

Breast cancer patients with many social ties have significantly lower rates of death and recurrence.

Patients share their personal stories with Specialty Pharmacy Times.

Metastasis affects as many as 5% of cancer patients around the world.

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.